Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab after IgE-specific immunoadsorption for food-induced anaphylaxis
2017-003627-30Phase 4Completed
- Sponsor
- Odense Research Center for Anaphylaxis
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in food allergy and anaphylaxis, sponsored by Odense Research Center for Anaphylaxis. Primary endpoints: Clinical reaction thresholds, Serum total and specific IgE and 2 more. Started Mar 2018; status: completed.
02
Drugs
omalizumab
03
Conditions
food allergyanaphylaxis
Beyond the preview
Go deeper on 2017-003627-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003627-30.